
CMTA’s $300K Investment in CRISPR for CMT2A
CMTA invests $300K in CRISPR gene editing for CMT2A at UCSF’s Gladstone Institutes, targeting MFN2 mutations to restore nerve function. GLENOLDEN, PA, UNITED STATES, March 25, 2025 /EINPresswire.com/ -- The Charcot-Marie-Tooth Association (CMTA …